This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| UK TAVI Registry | |
|---|---|
| Name | UK TAVI Registry |
| Established | 2007 |
| Country | United Kingdom |
| Type | Clinical registry |
| Jurisdiction | National Health Service |
| Site | Cardiac centres across England, Scotland, Wales, Northern Ireland |
UK TAVI Registry is a national clinical registry tracking transcatheter aortic valve implantation procedures across the United Kingdom, collecting procedural, device, and outcome data to inform practice and policy. It operates within the context of National Health Service (United Kingdom), collaborating with academic centres, professional societies, regulatory agencies, and device manufacturers to monitor safety and effectiveness. The registry informs clinicians, hospitals, and commissioners and is used in research linking procedural data to long‑term outcomes.
The registry was established amid expanding use of Transcatheter Aortic Valve Replacement technology following pivotal trials such as PARTNER trial, CoreValve US Pivotal Trial, and outcomes reported by centres including European Society of Cardiology, Society for Cardiovascular Angiography and Interventions, and specialist units at Royal Brompton Hospital, St Thomas' Hospital, and Royal Papworth Hospital. It was created to respond to concerns voiced by regulators like Medicines and Healthcare products Regulatory Agency and policy bodies such as National Institute for Health and Care Excellence about real‑world performance of devices produced by manufacturers including Edwards Lifesciences, Medtronic, and Boston Scientific. Early governance drew on models from registries like Society of Thoracic Surgeons database and national audits such as the Myocardial Ischaemia National Audit Project.
Governance arrangements involve professional bodies including British Cardiovascular Society, British Heart Foundation, and the Cardiovascular Society of Great Britain and Ireland, in partnership with health system commissioners and academic units at universities such as University of Oxford, University College London, University of Cambridge, Imperial College London, and University of Glasgow. Data collection standardizes procedural fields defined by international initiatives including the Valve Academic Research Consortium and leverages hospital informatics systems used at centres like Guy's and St Thomas' NHS Foundation Trust and Royal Free London NHS Foundation Trust. The registry links to administrative datasets maintained by NHS Digital and mortality records at Office for National Statistics (United Kingdom), enabling longitudinal follow‑up. Oversight committees include clinicians, statisticians from institutions like London School of Hygiene & Tropical Medicine and University of Edinburgh, and patient representatives associated with charities such as Cardiac Risk in the Young.
The registry captures indications, procedural approaches (transfemoral, transapical, transaortic), device models from vendors including Edwards Lifesciences, Medtronic, Boston Scientific, and adjunctive therapies such as balloon valvuloplasty and pacemaker implantation familiar to operators trained at centres like Papworth Hospital and Freeman Hospital. It records preoperative assessments referencing guidelines from European Association for Cardio-Thoracic Surgery, European Society of Cardiology, and British Cardiovascular Society and links to imaging data practices at units using modalities exemplified by Royal Brompton Hospital's cardiac imaging services. Patient selection criteria reflect risk stratification tools such as the EuroSCORE and the Society of Thoracic Surgeons Predicted Risk of Mortality model, and perioperative pathways engage multidisciplinary teams including cardiologists trained in centres like Royal Victoria Hospital and cardiac surgeons affiliated with Great Ormond Street Hospital.
Analyses have described in‑hospital mortality, stroke rates, vascular complications, paravalvular leak, and pacemaker requirement with comparative data paralleling reports from the PARTNER trial and CoreValve US Pivotal Trial. Registry outputs have documented reductions in procedural mortality over time similar to trends observed in registries such as Swedish TAVI Registry and German Aortic Valve Registry, and have influenced device recall responses coordinated with Medicines and Healthcare products Regulatory Agency and procurement decisions by NHS commissioners. Comparative effectiveness work links registry data to survival analyses conducted by teams at University of Oxford and Imperial College London.
The registry has underpinned peer‑reviewed publications in journals associated with organisations like British Medical Journal, The Lancet, and European Heart Journal and has been cited in guideline updates by National Institute for Health and Care Excellence and position statements from British Cardiovascular Society. Collaborative research has involved academic partners such as King's College London, University of Manchester, University of Leeds, and international consortia including participants from European Heart Network and Society for Cardiovascular Angiography and Interventions. Outputs have informed procurement frameworks across NHS trusts and contributed data for health technology assessment by bodies such as National Institute for Health and Care Excellence and procurement decisions in trusts like University Hospitals Birmingham NHS Foundation Trust.
Limitations include potential under‑reporting, variable completeness across centres including smaller units such as Kelda Hospitals and larger tertiary centres like John Radcliffe Hospital, and biases inherent in observational data noted by methodologists at London School of Economics and University of Cambridge. Data linkage obstacles involve governance frameworks at NHS Digital and confidentiality concerns engaging the Information Commissioner's Office. Device heterogeneity from manufacturers such as Edwards Lifesciences and Medtronic complicates comparative analyses, and changing procedural indications — influenced by trials like PARTNER 2 and SURTAVI trial — require adaptive case‑mix adjustment methods developed by statisticians at University of Bristol and University of Glasgow.
Planned developments include enhanced linkage with genomic resources at UK Biobank, integration with electronic health records used by trusts like Cambridge University Hospitals NHS Foundation Trust, adoption of standardized data models promoted by Health Data Research UK, and machine learning collaborations with research groups at Alan Turing Institute and DeepMind to predict outcomes. The registry aims to support randomized registry trials similar to initiatives led by Clinical Trials Unit (University of Oxford) and to provide post‑market surveillance partnering with regulators such as Medicines and Healthcare products Regulatory Agency and international registries like Transcatheter Valve Therapy Registry (USA).
Category:Medical registries in the United Kingdom